FIELD: medicine.
SUBSTANCE: invention relates to two embodiments of a method for preventing overdose of E7766 or a pharmaceutically acceptable salt thereof in a patient selected for treatment by means of E7766 or a pharmaceutically acceptable salt thereof. According to one of the embodiments, the method involves administering an initial amount of E7766 or a pharmaceutically acceptable salt thereof to said patient, wherein said patient receives an OATP1B1 or OATP1B3 inhibitor. Invention also relates to a method of treating cancer.
EFFECT: combined use of the above compounds enables to significantly increase the systemic effect of the E7766 compound.
44 cl, 5 dwg, 3 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DOSAGE FORMS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND THEIR APPLICATION | 2011 |
|
RU2609833C2 |
| SOLID DISPERSIONS CONTAINING APOPTOSIS PROMOTING PROTEINS | 2010 |
|
RU2550134C2 |
| PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF HELICOBACTER PYLORI | 2014 |
|
RU2671400C2 |
| IMPROVED THERAPEUTIC INDEX OF INHIBITORS AGAINST IMMUNE CHECKPOINT USING COMBINATION THERAPY INCLUDING PHY906 EXTRACT, SCUTELLARIA BAICALENSIS GEORGI (S) EXTRACT OR COMPOUND OF SUCH EXTRACTS | 2017 |
|
RU2753523C2 |
| MODIFIED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING FEBUXOSTAT | 2011 |
|
RU2602188C2 |
| COMBINATION THERAPY FOR TREATMENT OF MAMMARY GLAND CANCER | 2018 |
|
RU2764724C2 |
| COMBINATION THERAPY FOR HEPATOCELLULAR CARCINOMA | 2017 |
|
RU2769251C2 |
| COMBINED THERAPY WITH EZH2 INHIBITOR | 2018 |
|
RU2754131C1 |
| DOSAGE REGIMEN FOR AN ALPHA-ISOFORM SELECTIVE PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR | 2014 |
|
RU2680246C1 |
| METHODS AND COMPOSITIONS USING IMMUNOMODULATORY COMPOUNDS FOR TREATMENT AND MAINTENANCE OF CANCER AND OTHER DISEASES | 2004 |
|
RU2348407C2 |
